Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Sep 24:2018:18-0049.
doi: 10.1530/EDM-18-0049.

Refractory spontaneous hypoglycaemia: a diagnostic conundrum

Affiliations

Refractory spontaneous hypoglycaemia: a diagnostic conundrum

Seong Keat Cheah et al. Endocrinol Diabetes Metab Case Rep. .

Abstract

A frail 79-year-old lady with dementia presented with a 2-year history of frequent falls. Recurrent hypoglycaemic episodes were diagnosed and treated with continuous glucose infusion in multiple hospital admissions. Hypoadrenalism and hypothyroidism were ruled out. Whilst hypoglycaemic (blood glucose 1.6 mmol/L), both plasma C-peptide and proinsulin concentrations, were inappropriately elevated at 4210 pmol/L (174–960) and >200 pmol/L (0–7) respectively with plasma insulin suppressed at 12 pmol/L (0–180). Whilst reported cases of proinsulinoma are typically pancreatic in origin, radiological investigations of the pancreas in this patient did not identify abnormalities. Unexpectedly contrast CT identified a heterogeneously enhancing mass (6.6 cm) at the lower pole of the left kidney consistent with renal cell carcinoma. Non-islet cell tumour-induced hypoglycaemia has been associated with renal malignancy; however, a serum IGF2:IGF1 ratio measured at <10 effectively excludes this diagnosis. Concomitantly on the CT, extensive peripherally enhancing heterogeneous mass lesions in the liver were identified, the largest measuring 12 cm. A palliative approach was taken due to multiple comorbidities. On post-mortem, the kidney lesion was confirmed as clear cell renal carcinoma, whilst the liver lesions were identified as proinsulin-secreting neuroendocrine tumours. In conclusion, the diagnosis of proinsulinoma can be missed if plasma proinsulin concentration is not measured at the time of hypoglycaemia. In this case, the plasma insulin:C-peptide ratio was too high to be accounted for by the faster relative clearance of insulin and was due to proinsulin cross-reactivity in the C-peptide assay. In addition, the concomitant malignancy proved to be a challenging red herring. Learning points: •• Even in non-diabetics, hypoglycaemia needs to be excluded in a setting of frequent falls. Insulin- or proinsulinsecreting tumours are potentially curable causes. •• Whilst investigating spontaneous hypoglycaemia, if plasma insulin concentration is appropriate for the hypoglycaemia, it is prudent to check proinsulin concentrations during the hypoglycaemic episode. •• Proinsulin cross-reacts variably with C-peptide and insulin assays; the effect is method dependent. In this case, the discrepancy between the insulin and C-peptide concentrations was too great to be accounted for by the faster relative clearance of insulin, raising the suspicion of assay interference. The C-peptide assay in question (Diasorin liaison) has been shown to be 100% cross reactive with proinsulin based on spiking studies with a proinsulin reference preparation. •• Whilst reported cases of proinsulinoma and 99% of insulinomas are of pancreatic origin, conventional imaging studies (CT, MRI or ultrasound) fail to detect neuroendocrine tumours <1 cm in 50% of cases. •• The concomitant renal mass identified radiologically proved to be a red herring. •• In view of the rarity of proinsulinoma, no conclusive association with renal cell carcinoma can be established.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CT abdomen and pelvis of transverse (A, B) and coronal (B) view demonstrating the renal (white arrows) and liver lesions (black arrows) (C).
Figure 2
Figure 2
Kidney tumour. (A) H&E staining (×10). (B) Synaptophysin staining (×10). (C) Insulin immunoreactivity (×10).
Figure 3
Figure 3
Liver tumour. (A) H&E staining (×10). (B) Synaptophysin staining (×10). (C) Insulin immunoreactivity (×20).

References

    1. Murtha TD, Lupsa BC, Majumdar S, Jain D, Salem RR. A systematic review of proinsulin-secreting pancreatic neuroendocrine tumors. Journal of Gastrointestinal Surgery 2017. 21 1335–1341. (10.1007/s11605-017-3428-8) - DOI - PubMed
    1. Fadini GP, Maran A, Valerio A, Meduri F, Pelizzo M, Miotto D, Lanza C, Altavilla G, Avogaro A. Hypoglycemic syndrome in a patient with proinsulin-only secreting pancreatic adenoma (proinsulinoma). Case Reports in Medicine 2011. 2011 1–5. - PMC - PubMed
    1. Pérez-Pevida B, Idoate MÁ, Fernández-Landázuri S, Varo N, Escalada J. Hypoglycemic syndrome without hyperinsulinemia. A diagnostic challenge. Endocrine Pathology 2016. 27 50–54. (10.1007/s12022-016-9415-x) - DOI - PubMed
    1. Jensen RT, Cadiot G, Brandi ML, De Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R, et al ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 2012. 95 98–119. (10.1159/000335591) - DOI - PMC - PubMed
    1. de Groot JWB, Rikhof B, van Doorn J, Bilo HJG, Alleman MA, Honkoop AH, van der Graaf WT. Non-islet cell tumour-induced hypoglycaemia: a review of the literature including two new cases. Endocrine-Related Cancer 2007. 14 979–993. (10.1677/ERC-07-0161) - DOI - PubMed